Abstract
ObjectivesPsA and AS are chronic diseases associated with significant morbidities. National and international management guidelines include treatment with biologic therapies to improve outcomes and quality of life. There are limited real-world data on the patients’ journey from symptom onset to diagnosis and treatment in the UK. We use real-life, linked health data to explore patient pathways and the impact of biologics on patient outcomes.MethodsData from the Secure Anonymised Information Linkage databank in Wales were used to assess diagnosis and treatment of patients ≥18 years of age with at least one International Classification of Diseases, Tenth Revision code present for PsA/AS in rheumatology clinic data and at least one Read code present in primary care records. We investigated the use of biologics while exploring demographics, comorbidities and surgical procedures of 641 AS patients and 1312 PsA patients.ResultsAS patients were significantly younger at diagnosis and were predominantly male. The average time from presenting symptoms to diagnosis of AS and PsA was 7.9 (s.d. 5.5) and 9.3 (s.d. 5.5) years, respectively. The proportion of patients receiving biologic treatment was significantly higher in AS (46%) compared with PsA patients (28.8%); of these, 23.1% of AS and 22.2% of PsA patients stopped/switched a biologic. There was a significant reduction in primary care involvement, sick notes and disability living allowance for both AS and PsA patients following biologic initiation.ConclusionThis real-world descriptive study confirms that patients treated with biologics have reduced disability and time off work despite being initiated ∼13 years after the first symptoms and 6 years after diagnosis.
Highlights
PsA and AS are chronic inflammatory arthritic conditions associated with significant morbidity and poorer quality of life
There was a significant reduction in primary care involvement, sick notes and disability living allowance for both AS and PsA patients following biologic initiation
This real-world descriptive study confirms that patients treated with biologics have reduced disability and time off work despite being initiated $13 years after the first symptoms and 6 years after diagnosis
Summary
PsA and AS are chronic inflammatory arthritic conditions associated with significant morbidity and poorer quality of life. The diagnosis of these conditions is often delayed [1, 2] and this continues to be an issue in the UK [3]. The results demonstrated a diagnosis delay, with back pain as the presenting feature that led respondents to seek treatment. Misdiagnosis was an issue, with diagnoses of back problems, sciatica, orthopaedic issues, osteoarthritis, psychosomatic disorders and anxiety and depression associated with a longer time to AS diagnosis. More women were misdiagnosed with fibromyalgia and psychosomatic issues compared with men [2]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
